DPP-4
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin
... action, DPP-4 inhibitors are associated with low incidences of hypoglycemia when administered as monotherapy [13] or co-administered with agents that are not themselves associated with hypoglycemia [14, ...
9
Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
... A more detailed appreciation of how diabetes medications may affect a patient’s weight, and the implications of such interactions on key factors including insulin sensitivity, requires consideration of various ...
8
Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
... As the worldwide prevalence of diabetes mellitus increases, the incidence rates of concomitant compli- cations such as renal failure, coronary artery disease, stroke, and lower limb amputation are also increasing [1]. ...
11
DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho−/− mice
... 2]. DPP-4 inhibitors block the degradation of glucagon-like peptide-1 (GLP-1) and gastric inhibi- tory peptide (GIP), thereby prolonging the half-life of these ...incretins. DPP-4 inhibitors ...
12
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
... diabetes, DPP-4 inhibition is a treatment targeting pathophysiologically relevant aspects of the ...hypoglycemia. DPP-4 inhibition is therefore a novel and promising paradigm for treatment of ...
11
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
... for DPP-4 inhibition by linagliptin is comparable to that of the other DPP-4 inhibitors available ...for DPP-4 inhibition of 19 nM, 62 nM, and 50 nM, linagliptin demonstrated the ...
9
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
... and DPP-4 inhibi- tors are useful in the management of patients with type 2 diabetes over the spectrum of A1C levels, including drug-naive patients as well as those treated with other glucose-lowering ...
10
Dipeptidyl Peptidase 4 Inhibitors and Inflammation: Dpp 4 Inhibitors Improve Mean Pleatelet Volume and Gamma Glutamyl Transferase Level
... , DPP-4 inhibitor use was associated with improvement in liver function in pa- tients with liver damage, however, no statistically significant improvement was observed in normal liver function ...of ...
12
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
... some DPP-4 inhibitors and HF will require additional trials and potentially more ...the DPP-4 class effects on biomarkers, which propagates through to our final event rate ...of ...
11
Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan
... that DPP-4 inhibitors, an antidiabetic therapy with a low propensity for hypoglycemia, could be a valuable strategy to more safely manage treatment of T2DM with OAD therapy during Ramadan or other reli- ...
10
Quantum mechanical studies on spectral and electronic characteristics of Pioglitazonea potent DPP-4 inhibitor
... In this study, we have used the HF and DFT/B3LYP methods to investigate theoretical analysis on the geometries and electronic properties of Actos, a new generation of non-steroidal anti- diabetes drug (NSAID), which act ...
23
Synthesis of new DPP 4 inhibitors based on a novel tricyclic scaffold
... Type-2 diabetes is a chronic disease, characterized by ele- vated blood sugar levels, leading to severe vascular com- plications and an increased mortality risk. Dipeptidyl pep- tidase-4 (DPP-4), a ...
7
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
... a DPP-4 ...of DPP-4 inhibitors, though there had been no direct comparison of the effects of DPP-4 inhibitors on FABP4 ...
10
Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
... Results: A total number of 157,478 participants with T2DM were included. Seventy-six thousand and twenty six patients were assigned to the DPP-4 inhibitor group whereas 81,452 patients were assigned to the ...
9
Alogliptin: a new addition to the class of DPP-4 inhibitors
... At this time, there is a lack of long-term safety data for alogliptin and other DPP-4 inhibitors, especially those related to generalized DPP-4 inhibition. Studies of longer duration and ...
10
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
... of DPP-4 inhibitors and metformin (as one pill) showed favorable results in glycemic control because of favorable pharmacokinetic characteris- tics and complementary pharmacodynamic effects, which include ...
9
The impact of sitagliptin, inhibitor of dipeptidyl peptidase-4 (DPP-4), on the ADMA-DDAH-NO pathway in ischemic and reperfused rat livers
... Results. The increase in the initial level of ARG/ADMA0 (A/A) ratio in group S compared to group C verged on statistical significance. At 0.5 h and 4 h of reperfusion, the highest concentration of ADMA was found ...
8
Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
... with DPP-4 inhibitors, or the modest reduction in body weight associated with SGLT2 inhibitors may make combination therapy with these agents suitable for patients who are overweight or ...
15
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner
... observed at a glucose level of 11 mmol/L and not at 5 mmol/L. Interestingly, the glucose-dependency was also observed in GLP-1 mediated cardioprotection with infarct-limitation being observed at glucose levels of 7, 9, ...
9
Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE)
... and DPP-4 inhibitors provide beneficial effects against ath- erosclerosis [7, 20–22, 30, ...whether DPP-4 inhibitors affect atherosclerosis, did not show an additional effect of sit- agliptin ...
9